Product Summary
Antiviral API Sofosbuvir Powder CAS 1190307-88-0 Psi-7977 for HCV Treatment Sofosbuvir is a direct-acting antiviral (DAA) nucleotide analog inhibitor that targets the hepatitis C virus (HCV) RNA polymerase. It is a cornerstone of modern HCV treatment, enabling high cure rates with all-oral, ...
API Ingredients 99% Anti HCV API Sofosbuvir Crystalline Powder CAS 1190307-88-0
Basic Properties
Trading Properties
Antiviral API Sofosbuvir Powder
,Sofosbuvir Powder 1190307-88-0
,API Sofosbuvir Crystalline Powder
Antiviral API Sofosbuvir Powder CAS 1190307-88-0 Psi-7977 for HCV Treatment
| Parameter Item | Description |
| English Name | Sofosbuvir |
| Category | Direct-acting antiviral |
| Appearence | White to off-white crystalline powder |
| Molecular Formula | C22H29FN3O9P |
| Molecular Weight | 529.453 |
| Solubility | Soluble in water/methanol; slightly soluble in ethanol |
| Brand | Bovita |
| CAS Number | 1190307-88-0 |
- HCV replication inhibition: It is a prodrug that converts to its active form (GS-461203) in liver cells. This active metabolite integrates into the HCV RNA chain during replication, acting as a "chain terminator"-it binds to HCV NS5B polymerase (the enzyme essential for HCV RNA synthesis) and stops the formation of new viral RNA, thereby suppressing viral replication.
- Pan-genotypic activity: Unlike older HCV treatments, it exhibits broad efficacy across multiple HCV genotypes (e.g., genotypes 1-6), making it a core component of pan-genotypic HCV therapy.

-
- Combined with other DAAs (e.g., ledipasvir, velpatasvir, daclatasvir) to treat chronic HCV infection, including:
- Treatment-naive patients (no prior HCV therapy).
- Treatment-experienced patients (failed previous interferon-based or other DAA therapies).
- Patients with compensated or decompensated cirrhosis (liver scarring) or HIV/HCV coinfection.
- Shortens treatment duration (typically 8-12 weeks, vs. 24-48 weeks for older therapies) and achieves high sustained virologic response (SVR) rates (>95% in most cases), which is considered a "functional cure" for HCV.
- Combined with other DAAs (e.g., ledipasvir, velpatasvir, daclatasvir) to treat chronic HCV infection, including:
-
- No requirement for interferon (a component of older HCV therapies that caused severe side effects like fatigue and flu-like symptoms).
- High tolerability, with common side effects limited to headache, fatigue, and nausea.
- Effective across diverse patient populations, including those with liver comorbidities or coinfection
-
Ei like the price, cheap
-
Rgood quality cheapest price ,very nice
-
JI buy many times, i like it
Please use our online inquiry contact form below if you have any questions, our team will get back to you as soon as possible.